본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Annexin A1 in plasma from patients with bronchial asthma: its association with lung function
  • 작성일2019-05-09
  • 최종수정일2019-05-09
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 524
BMC Pulmonary Medicine, 2018, 18(1), 1─, DOI: https://doi.org/10.1186/s12890-017-0557-5

Annexin A1 in plasma from patients with bronchial asthma: its association with lung function

Sun-Hye Lee, Pureun-Haneul Lee; Byeong-Gon Kim; Hyun-Jeong Seo; Ae-Rin Baek; Jong-Sook Park; June-Hyuk Lee; Sung-Woo Park; Do-Jin Kim; Choon-Sik Park; An-Soo Jang

Abstract

    Background: Annexin-A1 (ANXA1) is a glucocorticoid-induced protein with multiple actions in the regulation of inflammatory cell activation. The anti-inflammatory protein ANXA1 and its N-formyl peptide receptor 2 (FPR2) have protective effects on organ fibrosis. However, the exact role of ANXA1 in asthma remains to be determined. The aim of this study was to identify the role of ANXA1 in bronchial asthma.
    Methods: In mice sensitized and challenged with ovalbumin (OVA-OVA mice) and mice sensitized with saline and challenged with air (control mice), we investigated the potential links between ANXA1 levels and bronchial asthma using ELISA, immunoblotting, and immunohistochemical staining. Moreover, we also determined ANXA1 levels in blood from 50 asthmatic patients (stable and exacerbated states).
    Results: ANXA1 protein levels in lung tissue and bronchoalveolar lavage fluid were significantly higher in OVA-OVA mice compared with control mice. FPR2 protein levels in lung tissue were significantly higher in OVA-OVA mice compared with control mice. Plasma ANXA1 levels were increased in asthmatic patients compared with healthy controls. Plasma ANXA1 levels were significantly lower in exacerbated patients compared with stable patients with bronchial asthma (p < 0.05). The plasma ANXA1 levels in controlled asthmatic patients were correlated with forced expiratory volume in 1 s (FEV1) (r = −0.191, p = 0.033) and FEV1/forced vital capacity (FVC) (r = −0.202, p = 0.024).
    Conclusion: These results suggest that ANXA1 may be a potential marker and therapeutic target for asthma.



  • 본 연구는 질병관리본부 연구개발과제(과제번호 2018-보건의료생물자원종합관리) 연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund(code 2018-보건의료생물자원종합관리) by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시+상업적이용금지+변경금지 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시+상업적이용금지+변경금지" 조건에 따라 이용할 수 있습니다.
TOP